Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C3PO: TriCAR19.20.22 T Cells for Relapsed or Refractory Lymphoid Malignancies
NCT07166419Phase 1Active, not recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TriCAR19.20.22 T cells in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and 2 more (2 cohorts), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Dose-limiting toxicity at 30 days and Recommended phase 2 dose at 30 days. Started Jan 2026; status: active, not recruiting.
02
Drugs
TriCAR19.20.22 T cells
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)chronic myeloid leukemia (CML)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT07166419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166419.